Ablation of c-Myb function might be an effective approach for the therapy of chronic myelogenous leukemia or other c-myb-dependent malignancies. To this end, we have previously used an intracellular anti-c-Myb single-chain antibody (sFv) to achieve the functional knockout of the c-Myb oncoprotein. In this study, we have employed a tetracycline-inducible system to control the expression of the sFv. A nuclear-localizing form of an anti-c-Myb sFv was cloned into a tet-regulated plasmid vector. Using a transient expression system in COS-1 cells, we observed that doxycycline (Dox) induced expression of the sFv in a dose-dependent manner, and that the sFv was localized mainly in the nucleus. The Dox-induced anti-c-Myb sFv also inhibited the transactivating activity of c-Myb in a dose-dependent manner. We subsequently confirmed the Dox-induced expression of the sFv in the leukemia cell line K562. Proliferation of the target leukemia cells was also inhibited. These results suggest that the anti-c-Myb sFv may represent a viable method for gene therapy of c-myb-dependent hematopoietic malignancies. Cancer Gene Therapy (2000) 7, 151-159
T he c-myb proto-oncogene is the cellular homolog of the viral oncogene v-myb, which is found in avian myeloblastosis virus and E26 retroviruses. 1, 2 The product of the c-myb gene, c-Myb, is a sequence-specific DNA binding transcriptional activator or repressor of various promoters [3] [4] [5] [6] [7] that is expressed in immature hematopoietic cells 8 -10 and also in a variety of tissues. [11] [12] [13] In this regard, during differentiation, the expression of c-myb is dramatically down-regulated in the context of normal hematopoietic development. 8, 9, 14, 15 In addition to its role in normal processes of differentiation, c-myb has been linked to the pathobiology of various neoplasms. Specifically, c-myb overexpression has been reported in human myelogenous leukemia 16 -18 and lymphoreticular malignancies. 16, 19 In addition, it has recently been shown that c-myb overexpression is observed in malignant cells of nonhematopoietic origin, including colon cancer, melanoma, breast cancer, neuroblastoma, and neuroepithelioma cells. 16,20 -23 Of note, in vitro experiments have shown that constitutive overexpression of an exogenous c-myb gene blocks differentiation in murine erythroleukemia cell lines. 24 -26 In addition, it has been reported that not only truncated c-Myb but also full-length c-Myb can transform avian myelomonocytic cells. 6, [27] [28] [29] In this regard, the importance of the c-myb proto-oncogene product in leukemia is also demonstrated by the inhibition of cellular proliferation by c-myb antisense oligonucleotides 30, 31 Although c-myb overexpression has been linked to the neoplastic phenotype, its precise role in this context has not been determined. 32 In this regard, we have developed a strategy for knockout of this oncoprotein by the intracellular single-chain antibody (Ab) (sFv) approach. We have demonstrated previously the functional knockout of the c-myb proto-oncogene product by an intracellularly expressed anti-c-Myb sFv. This suggested the utility of the sFv both in basic research, to aid in the precise definition of the function of c-myb, and in the development of gene therapy strategies for c-myb-dependent malignancies. 33 However, in these earlier studies, expression of the anti-c-Myb sFv was difficult to verify in human leukemia cells. Of note, in this context, leukemia cells are usually refractory to transduction; 34, 35 therefore, selection via a resistance gene is needed to expand the cell population expressing the transduced gene.
However, it is possible that constitutive expression of an anti-c-Myb sFv in such leukemia cells expressing c-myb might have a cytotoxic effect, resulting in deletion of the clones expressing the sFv gene. Thus, to address this issue, we employed a tetracycline (tet)-inducible retroviral vector system. 36 The regulation of gene expression is a useful tool for the selection of the cells expressing the transduced toxic gene. In this study, we report the tet-regulated expression of an anti-c-Myb sFv and demonstrate the inhibitory effects of the sFv on c-Myb function and on the proliferation of K562 human leukemia cells.
MATERIALS AND METHODS

Cell lines
K562 human chronic myelogenous leukemia cells and COS-1 African green monkey kidney cells were obtained from the American Type Culture Collection (Manassas, Va). The cells were maintained in Dulbecco's modified Eagle's medium/F12 (COS-1) or in RPMI 1640 (K562) tissue culture media (Mediatech, Hemdon, Va) supplemented with L-glutamine (2 mM), penicillin (100 international units/mL), streptomycin (25 g/mL), and 10% heat-inactivated fetal calf sera at 37°C in a humidified 5% CO 2 atmosphere.
Construction of anti-c-Myb sFv or c-Myb expression plasmids
Hybridoma 4/14 cells producing an anti-c-Myb monoclonal Ab were developed by Bading et al. 37 This hybridoma was used to generate the anti-c-Myb sFv constructs. The construction of this sFv has been described in detail elsewhere. 33 The nucleartargeted sFv expression plasmid pNuMybsFv was derived from the parental plasmid pcDNA3 (Invitrogen, Carlsbad, Calif). The vector has SfiI and NotI restriction enzyme sites for cloning of the sFv and contains DNA sequences encoding the simian virus 40 nuclear localization sequences (TMPP-KKKRKVGGAQPA) 38 plus the c-Myc tag at the C terminus of the sFv.
To generate the tet-inducible sFv system, we employed the tet-inducible retroviral vector pLRT-GFP, 36 which was constructed with a 1.9-kb EcoRI-XhoI fragment (rtTA-IRES-BSD), a 1.2-kb XhoI-SphI fragment (tetO-CMV-GFP), and a 4.9-kb EcoRI-SphI fragment from pLXSN. 39 The oligo doublestranded DNA containing the XhoI site was replaced with the green fluorescent protein (GFP) gene in pLRT-GFP, resulting in the plasmid pLRT-XhoI. Polymerase chain reaction-amplified cDNA of the nuclear-targeted anti-c-Myb sFv from pNuMybsFv was cloned between the XhoI site of pLRT-XhoI, resulting in pLRT-NuMybsFv. To construct the control vectors, we also cloned anti-Lmp1 sFv or the new generation of GFP (EGFP) 40 into pLRT-XhoI, resulting in the plasmids pLRT-NuLmpsFv or pLRT-EGFP, respectively (Fig 1) .
To achieve exogenous expression of the human c-Myb protein, the c-myb insert, c-mybp42 in pET-8c/p42, was cloned into pcDNA3 (pc-mybp42). 33 
Transfections
COS-1 cells were plated in 6-well or 24-well plates. After the cells reached 60 -80% confluency, they were transfected with plasmids using the adenovirus-poly-L-lysine (AdpL) delivery method. 41 Starting with Ad5 dL1014, which contains a genomic deletion in the E4 region, AdpL conjugates were constructed via the EDC-linkage method. These complexes were then mixed with plasmid DNA to form AdpL-DNA complexes. 42 For transient transfection experiments, the complexes were prepared as follows: conjugate-DNA complexes were formed by the sequential addition of 17 L of AdpL conjugate, 0.5-1 g of plasmid DNA diluted in 17 L of N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid-buffered saline pH 7.4 (HBS), and 0.7 g of poly-L-lysine (Sigma, St. Louis, Mo) diluted in 17 L of HBS. A total of 50 L of formed complexes were then mixed with 1 mL of media containing 2% fetal bovine serum and added to one well of each 6-well plate. After 1 hour, 1 mL of media containing 18% fetal bovine serum was added to the cells. When 24-well plates were used for the experiments, the scale of the volume was reduced to 20%. When K562 cells were used for the experiments, 10 7 K562 cells were transfected with 20 g of pLRT-NuMybsFv, pLRTNuLmpsFv, or pLRT-EGFP by electroporation (Gene Pulser II, Bio-Rad, Hercules, Calif; 1.0 kV/cm, 960 F). The cells were cultured in the media for 24 hours, and 5 g/mL of blasticidine S (Calbiochem, La Jolla, Calif) was added to the cells. After 2 weeks, selected cells named K562/MybsFv, K562/LmpsFv, or K562/EGFP were used for the experiments.
Expression of tet-inducible anti-c-Myb sFv
After transient transfection (COS-1) or selection for 2 weeks (K562), doxycycline (Dox) (1 g/mL) was added to the cells and culture was continued. At 48 hours or at the described timepoints, expression of the sFv protein was detected by immunoblotting or immunofluorescent staining.
Immunoblot analysis
For the detection of anti-c-Myb sFv protein, 30 g of the cell lysate protein was separated on a 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE). After electrophoresis, the protein was transferred onto a nitrocellulose membrane (Bio-Rad). An anti-Myc tag monoclonal Ab (Pharmacia Biotech, Piscataway, NJ), at a dilution of 1/3000 was added to the membrane as the primary Ab. After incubation, a Figure 1 . Schema of the tet-inducible retroviral vector of sFvs and EGFP. The cassette, cloned into a Moloney murine leukemia virus retroviral vector pLXSN backbone, consists of the gene-encoding packaging signal (), the reverse tet-controlled transactivator (rtTA), the internal ribosome entry site from the encephalomyocarditis virus (IRES), the blasticidine S deaminase (BSD), a heptamerized tet operator sequence (tetO), the minimal human cytomegalovirus immediate early promoter designated P hCMV*Ϫ1 (CMV), and sFvs or EGFP. LTR is the long terminal repeat of Moloney murine leukemia virus. The effector, Dox, is necessary to binding the transactivator to its specific DNA target sequence (tetO).
horseradish peroxidase-conjugated goat anti-mouse, or antirabbit immunoglobulin G (IgG) (The Jackson Laboratory, Bar Harbor, Me) was added to the membrane at a dilution of 1/3000, and incubation was continued for an additional hour. The immunoblot was developed by the Renaissance reagent system (DuPont, Boston, Mass) according to the manufacturer's instructions.
Immunofluorescence staining
To detect the localization of the anti-c-Myb sFv in situ, COS-1 cells plated on glass coverslips were transfected with plasmids and 1 g/mL of Dox was added. After 48 hours, COS-1 cells were washed and fixed by phosphate-buffered saline containing 4% paraformaldehyde for 10 minutes. Next, cell membranes were permeabilized with phosphate-buffered saline containing 0.2% Triton X-100 (Sigma). An anti-c-Myc polyclonal Ab at a dilution of 1/400 was added and incubated for 1 hour at room temperature, followed by incubation with fluorescein isothiocyanate-conjugated polyclonal goat anti-rabbit IgG Ab at a dilution of 1/400 for an additional hour. The stained cells were then evaluated by immunofluorescence microscopy.
Transcriptional assays
To observe the inhibitory effect of anti-c-Myb sFv on the transcriptional activity of c-Myb, we employed a human c-myc promoter-luciferase fusion gene, pMyc-Luc 28 as a target for c-Myb. In this regard, it has been reported that c-Myb stimulates the human c-myc promoter, P1 and P2. 29 Cotransfection of plasmids pMyc-Luc and pc-mybp42 into COS-1 cells showed the stimulatory effect of c-Myb on the c-myc promoter. After establishing the transcriptional assay system, we also cotransfected pLRT-NuMybsFv as a third plasmid. COS-1 cells plated in 24-well plates were transfected with these plasmids by the AdpL method. Effector (pc-mybp42), reporter (pMyc-Luc), and inhibitor (pLRT-NuMybsFv) plasmids were transfected in relative amounts of 40:1:10 -40. At 48 hours posttransfection, the cells were lysed in 100 L of lysis buffer (Promega, Madison, Wis). A total of 10 L of each sample were subsequently mixed with 50 L of luciferase assay reagent (Promega) according to the manufacturer's instructions, and duplicate determinations of triplicate samples were assayed in a Berthold luminometer. The luciferase activity counted for 10 seconds was standardized by the amount of protein.
Cytotoxicity assays
K562/MybsFv, K562/LmpsFv, or K562/EGFP cells were plated into 96-well plates (5000 cells/well), and Dox was added to half the wells of the plates. After 24 hours, escalating concentrations of adriamycin (Calbiochem) were added. The relative percentage of viable cells was determined at 72 hours after incubation by a 3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium (MTS) reduction assay according to the manufacturer's instructions (Promega). The absorbance at 490 nm was measured by a microplate reader (Bio-Rad).
Statistical analysis
The statistical significance of differences was determined by Student's t test.
RESULTS
Transient expression of anti-c-Myb sFvs in COS-1 cells
To observe the time course of expression of the Doxinduced sFv, COS-1 cells transfected with pLRTNuMybsFv by the AdpL method were induced by 1 g/mL of Dox. After induction, the cell lysate samples were collected at the described timepoints, and the expression of the sFv protein was determined by immunoblot analysis (Fig 2A) . Although the expression of an anti-c-Myb sFv was clearly detected at 24 hours postinduction, the expression level of the sFv increased to 120 hours postinduction. Of note, a low level of expression of the sFv in the absence of induction by Dox was detected from 48 hours to 120 hours, indicating the leakiness in the tet-inducible system.
We subsequently investigated the dose-dependent expression of the sFv. COS-1 cells transfected with pLRTNuMybsFv by the AdpL method were induced by vari- ous concentrations of Dox. After 48 hours, the expression of the sFv protein was determined by immunoblot analysis (Fig 2B) . The sFv was induced by Dox in a dose-dependent manner. The expression reached a peak level at concentration of Dox of Ն0.3 g/mL. The negative control cells transfected with pLRT-EGFP did not express the sFv. In this experiment, the cells also expressed a low level of the sFv in the absence of Dox.
Subcellular localization of an anti-c-Myb sFv in COS-1 cells
Next, we observed the expression of an anti-c-Myb sFv by immunofluorescent staining. COS-1 cells were transfected with pLRT-NuMybsFv or pcDNA3 by the AdpL method and induced by Dox. At 48 hours postinduction, the sFv protein was observed by immunofluorescent staining. Although a small number of the cells expressed the sFv without Dox (Fig 3B) , the expression was dramatically stimulated by Dox induction (Fig 3C) . Of note, the anti-c-Myb sFv includes the simian virus 40 nuclear leader peptide; therefore, the sFv was expressed mainly in the nucleus (Fig 3D) . Thus, these studies confirmed that the Dox-induced anti-c-Myb sFv was expressed in the correct subcellular compartment in COS-1 cells to permit inhibition of the DNA-binding of c-Myb protein in the nucleus.
Functional knockout of c-Myb by Dox-induced anti-c-Myb sFvs
We have reported previously that an anti-c-Myb sFv inhibited the transactivation activity of c-Myb. 33 We subsequently observed the effect of the Dox-induced sFv on the transactivation activity of c-Myb. In this regard, we employed a human c-myc promoter-luciferase fusion gene. Previous studies have shown that the human c-mybp42 expression plasmid pc-mybp42 strongly stimulated the human c-myc promoter, including the P1 and P2 regions. 43 In our experiments, we used the plasmid pMyc-Luc, which includes the P1 and P2 regions of the human c-myc promoter followed by the luciferase gene. 44 Dox was added to the cells at the time of transfection, and the cells were incubated for an additional 48 hours. The c-Myb expression plasmid stimulated the luciferase activity by several fold (Fig 4) . Cotransfection of the COS-1 cells with pLRTNuMybsFv, pc-mybp42, and pMyc-Luc showed that the nuclear form of the anti-c-Myb sFv inhibited the transactivating activity of c-Myb in a dose-dependent manner (Fig 5) . Low amounts of pLRT-NuMybsFv (pc-mybp42 to pLRT-NuMybsFv ϭ 4:1) had no inhibitory effect on the function of c-Myb. However, a higher amount of the sFv expression plasmid (pc-mybp42 to pLRTNuMybsFv ϭ 1:1) inhibited 50% of the stimulatory effect of c-Myb. The control vector pLRT-NuLmpsFv showed no effect on the transactivation activity of c-Myb (Fig 4) . These results confirmed that the Dox-induced nuclear form of anti-c-Myb sFv specifically blocked the function of c-Myb.
Cytotoxic effect of an anti-c-Myb sFv on leukemia cells
To evaluate the effects of the anti-c-Myb sFv, K562 human leukemia cells were transfected with pLRTNuMybsFv and selected by blasticidine S for 2 weeks. After the selection, we identified three different cultures of K562 cells expressing the Dox-induced sFv (Fig 5) . The expression level of the sFv was lower than that of COS-1 cells. In the preliminary experiments, we observed the decline of the expression of anti-c-Myb sFv after Ն2 weeks, or during the cloning. Therefore, we used the K562 cells just after 2 weeks of selection by blasticidine S. The K562/MybsFv cells (culture 3) were plated into 96-well plates (5000 cells/well), and Dox (1 g/mL) was added to half the wells. After 24 hours of culture, cells were treated with various concentrations of adriamycin for 72 hours, and cell proliferation was determined by an MTS assay. In the absence of the chemoagent, Dox-induced anti-c-Myb sFv reduced cell growth by 40% in K562/MybsFv cells compared with the noninduced cells (Fig 6B) . Dox induction had no significant inhibitory effect on the cell growth in the control pLRT-EGFP transfectant, K562/EGFP (Fig 6A) . The data also demonstrate a reduction of the 50% inhibitory concentration. The 50% inhibitory concentration of the 001 g) , effector plasmid (pc-mybp42) (0.04 g), and inhibitor plasmid (pLRT-NuMybsFv) (1ϩ, 0.01 g; 2ϩ, 0.02 g; 3ϩ, 0.04 g); next, 1 g/mL of Dox was added to the media. Luciferase activity was measured at 48 hours postinduction. The anti-Lmp1 sFv expression vector pLRT-NuLmpsFv was used as a control. The EGFP expression vector pLRT-EGFP was used to adjust the total amount of plasmids added into an each well. Plasmid (Ϫ), negative control cells; pMyc-Luc, basal activity of the c-myc promoter. Results were expressed as the mean Ϯ SD. n ϭ 4. **, P Ͻ .01; ***, P Ͻ .001; compared with a pLRT-NuMybsFv-negative control (pMyc-Luc, pc-mybp42, pLRT-EGFP).
K562/EGFP and the K562/MybsFv cells was 50 ng/mL and 1.5 ng/mL, respectively.
DISCUSSION
In this report, we have constructed a Dox-inducible sFv expression plasmid and have demonstrated the functional knockout of the c-Myb proto-oncoprotein by an intracellular anti-c-Myb single-chain Ab. In a previous study, we found it difficult to detect the expression of an anti-c-Myb sFv in K562 leukemia cells. We speculated that the K562 cells expressing the anti-c-Myb sFv could not survive and were soon deleted from the population of the cells. To overcome this disadvantage, we employed a tet-inducible retroviral vector system. Recently it has been reported that a retroviral vector that contains all of the components required for the tet-regulated system allows easy delivery of controllable genes to both cultured cells and animals. 36 Using this system, we observed that the Dox-induced anti-c-Myb sFv was expressed in COS-1 cells and could be targeted to the nucleus. In our previous study, the nuclear-targeted sFv was expressed strictly in the nucleus. 33 Although the Dox-induced sFv was expressed mainly in the nucleus, it was also observed in the cytoplasm in a subpopulation of the cells. It is possible that the different sequence of the N-and C-terminal amino acids of these nuclear-targeted sFvs caused slightly different subcellular localization patterns.
To confirm the function of the sFv, we employed a method using the c-myc promoter described in a previous report. 33 The Dox-induced anti-c-Myb sFv also inhibited the transactivation activity of c-Myb in a dose-dependent manner. In this cotransduction system, each cell was transfected with three plasmids at different ratios. Therefore, it may be speculated that the function of c-Myb might be completely inhibited in a subpopulation of the cells. In contrast, a control vector expressing anti-Lmp1 sFv had no inhibitory effect on the function of c-Myb.
We subsequently conducted experiments using the human leukemia cell line K562. We initially tried to establish stable clones expressing the Dox-inducible sFv. Although we could establish K562 clone-expressing Dox-inducible EGFP or control anti-Lmp1 sFv, we found it hard to establish stable transfectants expressing the Dox-inducible anti-c-Myb sFv. After a selection period by blasticidene S of Ն2 weeks, the expression level of the sFv gradually decreased. Even after recloning, the sFv-positive cells were gradually deleted. It is possible that the low leaky expression of the anti-c-Myb sFv protein in the absence of induction by Dox kills the K562 cells during selection. Therefore, we used the K562 cells transfected with pLRT-NuMybsFv after 2 weeks of selection. At that timepoint, some portion of the cells could be induced by Dox and express an anti-c-Myb sFv. Using this population of the cells, we confirmed the inhibitory effect of an anti-c-myb sFv on the proliferation of the leukemia cells expressing c-Myb. Dox-induced anti-Lmp1 sFv had no antiproliferative effects on K562/ LmpsFv cells (data not shown) as well as Dox-induced EGFP-N1. The Dox-induced-ratio of K562/EGFP or K562/LmpsFv was higher than that of K562/MybsFv. After 2 weeks of selection by blasticidine S, nearly 100% of the cells expressed EGFP-N1 by Dox induction (data not shown). In addition, we have established that the anti-c-Myb sFv has no antiproliferative effects on COS-1 cells. 33 These data suggest that the effects of anti-c-Myb sFv are specific for the functional knockout of c-Myb.
The principal advantage of the tet-inducible retroviral vector system is to control the toxicity of the gene product on the cells. 45, 46 Although there was weak leaky expression of the anti-c-Myb sFv, we achieved the regulation of the expression of sFv in mammalian cells using the system, and observed the inhibitory effects of an anti-c-Myb sFv on the proliferation of human leukemia cells as well as on the function of c-Myb. In previous studies, c-myb antisense oligonucleotides have shown an inhibitory effect on the growth of malignant cells expressing c-myb. 30, 31, 47, 48 In our experiments, Dox-induced expression of anti-c-Myb sFv reduced cell growth by 40% in the absence of the chemoagent. It supported previous observations that anti-myb oligodeoxynucleotides inhibited the leukemia cell proliferation. In the context of the gene therapy, we now have no high efficiency transduction vector or methods for leukemia cells. The size of the sFv cDNA is Ͻ1 kb, and the sFv gene is easily cloned into many types of vectors. Recently, we developed a genetically modified adenovirus vector, Ad5lucRGD. 49 This vector showed highly efficient transduction of the reporter gene into a human acute lymphoblastic leukemia cell line, TOM-1 (data not shown). Herpes simplex vector also has some advantage for transduction into lymphocytes. 50 In the future work, we will test the effects of anti-c-Myb sFv on various cancer cells as well as hematopoietic malignant cells. Figure 5 , K562/ MybsFv or K562/EGFP cells were plated into 96-well plates (5000 cells/ well). Dox was added to half of the wells. After 24 hours, various concentrations of adriamycin were added. After 72 hours, the cell proliferation was assayed by MTS reduction assay according to the manufacturer's instructions; next, the absorbance at 490 nm was measured by a microplate reader. Results were expressed as the mean Ϯ SD. n ϭ 6. K562/EGFP, K562 cells transfected with pLRT-EGFP; K562/ MybsFv, K562 cells transfected with pLRT-NuMybsFv. Ⅺ and E, Dox(Ϫ); f and F: Dox(ϩ). *, P Ͻ .05; **, P Ͻ .01; ***, P Ͻ .001; compared with Dox(Ϫ) control.
